Epigenomics

Epigenomics AG, founded in 1998 and publicly listed in Frankfurt (ECX), has transitioned from a developer of its own colorectal cancer test (Epi proColon) to a pure holding company. Its mission is to manage assets and invest in companies, primarily in Germany and abroad, that are pioneering minimally invasive blood tests for cancer detection. The company's strategy leverages its legacy expertise in biomarker development and regulatory pathways to identify high-potential investment targets within the liquid biopsy sector, aiming to generate shareholder value through capital allocation rather than direct product commercialization. Recent financials indicate a significantly reduced operational loss as it executes this new strategic direction.

As a holding company, Epigenomics AG does not own a single technology platform but invests in companies developing platforms for minimally invasive cancer detection, primarily based on circulating tumor DNA (ctDNA) and epigenetic biomarkers like DNA methylation.

Epigenomics competes not with diagnostic firms but with healthcare-focused venture capital firms and corporate venture arms. Its differentiation is its specialized focus on liquid biopsy and the operational experience of its leadership in this specific field.